The application relates to application of
ginkgo biloba
lactone A in preparation of drugs against
white spot syndrome, aiming at the problem that
effective treatment drugs are still lacking for the destructive damage of
white spot syndrome virus (WSSV) to aquatic crustaceans, and providing a new application of
ginkgo biloba
lactone A; through in-vitro experiment of Hpt cells of astacus leptodactylus and in-vivo feeding experiment of astacus leptodactylus, it is verified that the
ginkgo biloba
lactone A can significantly inhibit WSSV replication at a concentration of 100 muM; the astacus leptodactylus is fed with 40 mg / kg feed for 10 days, the
survival rate after being infected with WSSV is increased by about 53.3%, meanwhile, the expression of immune-related genes is up-regulated, the
apoptosis rate of blood cells is reduced, and the
virus replication is significantly inhibited; a safe and efficient new
drug for the prevention and control of WSSV in aquatic breeding is provided, and has important industrial application value.